Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Topical Versus Systemic Treatment in Postherpetic Neuralgia and Diabetic Polyneuropathic Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects with \>= 18 years of age~* Intact skin in the area of topical treatment~* Creatinine clearance CLCR \>= 30 mL/min~* NRS-3 \> 4 (recalled average pain intensity during the last 3 days)~Subjects with DPN~* Controlled, treated type 1 or 2 diabetes mellitus with glycosylated hemoglobin (Hba1c)\<= 11%~* Painful, distal symmetrical, sensomotor polyneuropathy of the lower extremities for \>= 3 months (below the knees on both extremities) with at least 2 of the following symptoms present: burning, sensation, tingling or prickling, numbness from time to time, painful heat or cold sensation (e.g. warm or cold water)~Subjects with PHN~* Subjects with PHN and neuropathic pain present for \>= 3 months after healing of the herpes zoster skin rash.~* Without neurolytic neurosurgical therapy for their condition.~Exclusion Criteria:~General~* Evidence or history of alcohol, medication or drug abuse and/or dependency in the past 2 years, unstable psychological personality requiring intermittent or permanent treatment.~* Psychiatric illness (subjects with well-controlled depression or anxiety disorder may participate if they are not taking any of the prohibited medications defined (below), epilepsy or suicide risk.~* Pregnant or breastfeeding women~* Women of childbearing potential who are sexually active without satisfactory contraception for at least 28 days prior to enrollment, during the trial, and until 28 days after the follow-up visit.~* Subjects with severe cardiac impairment e.g. NYHA class \> 3, myocardial infarction less than 6 months prior to enrollment, and/or unstable angina pectoris.~* Subjects with severe hepatic disorder and/or AST or ALT \>= 3x the upper limit of normal.~* Subjects with known or suspected severe renal failure (CLCR \< 30 mL/min).~* Anticipated need for surgery during the trial, requiring at least regional or general anesthesia.~* Subjects who are undergoing active treatment for cancer, are known to be infected with HIV or being acutely and intensively immunosuppressed following transplantation.~* Participation in another trial of investigational medicinal products or devices parallel to or less than 1 month before entry into the trial, or previous participation in this trial.~Trial specific:~* Any concomitant use of drugs for the treatment of neuropathic pain or commonly used for the treatment of neuropathic pain.~* Use of transcutaneous electrical nerve stimulations (TENS) after enrollment.~* CLCR \< 30 mL/min~* Evidence of another cause for pain in the area of neuropathic pain such as lumbar radiculopathy, surgery trauma, restless legs syndrome, if this coud confound the assessment or self-evaluation of the neuropathic pain.~* Presence of other severe pain that could confound the assessment or self-evaluation of the neuropathic pain.~* History of malignancy within the past 5 years (with the exception of basal cell carcinoma).~Subjects with PHN~* Active herpes zoster lesion or dermatitis of any origin at the affected site with PHN.~* Subjects who had neurological ablation by block or neurosurgical intervention for control of pain in PHN.~Subjects with DPN~* No palpable pulse of the arteria dorsalis pedis in both feet.~* Clinical signs for venous insufficiency and/or postthrombotic syndrome Sage III/IV (i.e. extensive varicoses)~* Ulcers on the lower extremities.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None
- 3 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).